DermTech study shows DMT’s effectiveness as rule-out test for all skin types

DermTech reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test DMT across all skin types in the real-world clinical setting. The peer-reviewed study entitled, “Non-invasive gene expression analysis rules out melanoma with high negative predictive value regardless of skin phototype” was presented at the Winter Clinical Dermatology Conference . Using follow-up information and biopsy results from a large registry database that also served as the basis for the Company’s recently completed Trust 2 Study, this study compared the DMT’s performance in patients with Fitzpatrick skin phototypes I-III to its performance in patients with skin phototypes IV-VI . As in prior DMT studies, lesions on acral skin were excluded because the thicker skin on acral sites may interfere with the test’s non-invasive sample collection method. “This study demonstrated that regardless of a patient’s skin type, the DMT can help clinicians rule out melanoma non-invasively, with an NPV of over 99%,” said Loren Clarke, M.D., chief medical officer, DermTech. “A high NPV means a suspicious pigmented lesion that tests negative is unlikely to be a melanoma. The DMT provides genomic information that can help guide biopsy decisions for suspicious pigmented lesions across all skin types.”